Patient-centered approach to elicit and compare the treatment goals of patients with tardive dyskinesia, their care partners, and healthcare providers
Objective: To elicit and compare the treatment goals of patients with tardive dyskinesia (TD), their care partners, and healthcare providers (HCP). Background: Tardive dyskinesia (TD)…Regardless of impaired renal function, negative myoclonus can be induced by gabapetin and pregabalin
Objective: This study evaluated pregabalin- or gabapentin-induced negative myoclonus according to renal function. Background: Gabapentin and pregabalin are commonly used to control neuropathic pain and epilepsy.…Drug-induced Negative Myoclonus: A Case Report
Objective: To report on a case of drug-induced negative myoclonus in a patient with a complex oral therapy. Background: Myoclonus is a shock-like jerk due…Quercetin administration abrogates the Parkinson’s disease (PD)-like motor and non-motor symptoms and attenuates the behavioral, neurochemical and biochemical deficits induced by rotenone toxicity in rats
Objective: The present study was carried out to investigate the preventive and therapeutic effects of quercetin (a flavonol) against rotenone-induced neurotoxicity. Background: Rotenone (pesticide) induced…Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia
Objective: To examine long-term outcomes in adults with tardive dyskinesia (TD) who received once-daily valbenazine (VBZ) 40 mg or had a dose reduction from 80…Steroid-responsive myoclonus in the context of pembrolizumab treatment: a novel neurological phenotype.
Objective: To outline a novel immunologically-mediated neurological adverse event associated with the use of a medication class which has an expanding range of applications [1].…Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease
Objective: Objective of our study was to evaluate protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease. Background: Parkinson’s disease (PD),…Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome
Objective: To report a case of clonazepam induced withdrawal emergent dyskinesia. Background: Withdrawal emergent syndrome was first described in 1973 when it was noticed that…Drug-Induced Parkinsonism May Persist Beyond Two Years After Discontinuation of Dopamine Transmission Blocking Agents
Objective: To demonstrate that patients with drug-induced parkinsonism (DIP) can remain symptomatic beyond 6 months, what majority of literature suggests, after withdrawal of causative agents.…Moving ear syndrome secondary to bromopride and response to botulinum toxin
Objective: Report a case of a rare drug-induced movement disorder, the moving ear syndrome, describe its phenomenology and its treatment with botulinum toxin Background: Since…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.